http://purl.org/np/RAB-u-hxrlyauBzF8c5oHiQzT-UYXEmoz26j5J7hXULXY#Head
http://purl.org/np/RAB-u-hxrlyauBzF8c5oHiQzT-UYXEmoz26j5J7hXULXY
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAB-u-hxrlyauBzF8c5oHiQzT-UYXEmoz26j5J7hXULXY#assertion
http://purl.org/np/RAB-u-hxrlyauBzF8c5oHiQzT-UYXEmoz26j5J7hXULXY
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAB-u-hxrlyauBzF8c5oHiQzT-UYXEmoz26j5J7hXULXY#provenance
http://purl.org/np/RAB-u-hxrlyauBzF8c5oHiQzT-UYXEmoz26j5J7hXULXY
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAB-u-hxrlyauBzF8c5oHiQzT-UYXEmoz26j5J7hXULXY#pubinfo
http://purl.org/np/RAB-u-hxrlyauBzF8c5oHiQzT-UYXEmoz26j5J7hXULXY
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAB-u-hxrlyauBzF8c5oHiQzT-UYXEmoz26j5J7hXULXY#assertion
http://purl.obolibrary.org/obo/DOID_13189
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAB-u-hxrlyauBzF8c5oHiQzT-UYXEmoz26j5J7hXULXY#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_13189
http://purl.org/np/RAB-u-hxrlyauBzF8c5oHiQzT-UYXEmoz26j5J7hXULXY#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAB-u-hxrlyauBzF8c5oHiQzT-UYXEmoz26j5J7hXULXY#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB00959
http://purl.org/np/RAB-u-hxrlyauBzF8c5oHiQzT-UYXEmoz26j5J7hXULXY#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAB-u-hxrlyauBzF8c5oHiQzT-UYXEmoz26j5J7hXULXY#association
http://www.w3.org/2000/01/rdf-schema#label
when oral therapy is not feasible and the strength dosage form and route of administration of the drug reasonably lend the preparation to the treatment of the condition the intramuscular use of methylprednisolone acetate injectable suspension is indicated as follows allergic states control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma atopic dermatitis contact dermatitis drug hypersensitivity reactions seasonal or perennial allergic rhinitis serum sickness transfusion reactions dermatologic diseases bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus severe erythema multiforme stevens johnson syndrome endocrine disorders primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the drug of choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia hypercalcemia associated with cancer nonsuppurative thyroiditis gastrointestinal diseases to tide the patient over a critical period of the disease in regional enteritis systemic therapy and ulcerative colitis hematologic disorders acquired autoimmune hemolytic anemia congenital erythroid hypoplastic anemia diamond blackfan anemia pure red cell aplasia select cases of secondary thrombocytopenia miscellaneous trichinosis with neurologic or myocardial involvement tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy neoplastic diseases for palliative management of leukemias and lymphomas nervous system acute exacerbations of multiple sclerosis cerebral edema associated with primary or metastatic brain tumor or craniotomy ophthalmic diseases sympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids renal diseases to induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus respiratory diseases berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy idiopathic eosinophilic pneumonias symptomatic sarcoidosis rheumatic disorders as adjunctive therapy for short term administration to tide the patient over an acute episode or exacerbation in acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require low dose maintenance therapy for the treatment of dermatomyositis polymyositis and systemic lupus erythematosus see warnings methylprednisolone acetate injectable suspension is indicated as adjunctive therapy for short term administration to tide the patient over an acute episode or exacerbation in acute gouty arthritis acute and subacute bursitis acute nonspecific tenosynovitis epicondylitis rheumatoid arthritis synovitis of osteoarthritis methylprednisolone acetate injectable suspension is indicated for intralesional use in alopecia areata discoid lupus erythematosus keloids localized hypertrophic infiltrated inflammatory lesions of granuloma annulare lichen planus lichen simplex chronicus neurodermatitis and psoriatic plaques necrobiosis lipoidica diabeticorum methylprednisolone acetate injectable suspension also may be useful in cystic tumors of an aponeurosis or tendon ganglia
http://purl.org/np/RAB-u-hxrlyauBzF8c5oHiQzT-UYXEmoz26j5J7hXULXY#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RAB-u-hxrlyauBzF8c5oHiQzT-UYXEmoz26j5J7hXULXY#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAB-u-hxrlyauBzF8c5oHiQzT-UYXEmoz26j5J7hXULXY#association
https://w3id.org/biolink/vocab/relation
https://schema.org/TreatmentIndication
https://identifiers.org/drugbank:DB00959
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAB-u-hxrlyauBzF8c5oHiQzT-UYXEmoz26j5J7hXULXY#provenance
http://purl.org/np/RAB-u-hxrlyauBzF8c5oHiQzT-UYXEmoz26j5J7hXULXY#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAB-u-hxrlyauBzF8c5oHiQzT-UYXEmoz26j5J7hXULXY#pubinfo
http://purl.org/np/RAB-u-hxrlyauBzF8c5oHiQzT-UYXEmoz26j5J7hXULXY#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAB-u-hxrlyauBzF8c5oHiQzT-UYXEmoz26j5J7hXULXY#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RAB-u-hxrlyauBzF8c5oHiQzT-UYXEmoz26j5J7hXULXY#sig
http://purl.org/nanopub/x/hasSignature
Vg71pwUd8w2xEkAZ9Y4ZsRBA7A1F3wk0OAaPFGALHQR30mQi7ir7EO48c4FcDoXPGqFumTtnQ3AleL/9xbsFeWmO4vdylUkoNLaNc9Fbar95w/aYyC3pgXeunmrxJpZnZD8Qdw99H6sj7DbF0cT7WF2RPoqZbbB5dfvq+gN6LbM=
http://purl.org/np/RAB-u-hxrlyauBzF8c5oHiQzT-UYXEmoz26j5J7hXULXY#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAB-u-hxrlyauBzF8c5oHiQzT-UYXEmoz26j5J7hXULXY
http://purl.org/np/RAB-u-hxrlyauBzF8c5oHiQzT-UYXEmoz26j5J7hXULXY
http://purl.org/dc/terms/created
2021-06-14T08:25:04.345+02:00
http://purl.org/np/RAB-u-hxrlyauBzF8c5oHiQzT-UYXEmoz26j5J7hXULXY
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAB-u-hxrlyauBzF8c5oHiQzT-UYXEmoz26j5J7hXULXY
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAB-u-hxrlyauBzF8c5oHiQzT-UYXEmoz26j5J7hXULXY
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAB-u-hxrlyauBzF8c5oHiQzT-UYXEmoz26j5J7hXULXY
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs